Celcuity

76 articles about Celcuity

• Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

  12/9/2022

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that updated results from a Phase 1b trial evaluating gedatolisib were presented during a Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium (SABCS).

• Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

  12/7/2022

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib plus fulvestrant with and without palbociclib for the treatment of patients with HR+/HER2- advanced breast cancer.

• Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

  9/14/2022

  Celcuity Inc. today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors.

• Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/11/2022

  Celcuity Inc., a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, announced financial results for the second quarter ended June 30, 2022 and other recent business developments.

• Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

  8/4/2022

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the stock market close on Thursday, August 11, 2022.

• Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference

  8/3/2022

  Celcuity Inc., a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be held in Boston on August 8-11, 2022.

• 

  FDA Weekly Review: Avadel, Eton, Pfizer, Celcuity and Others

  7/22/2022

  FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.

• Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer

  7/18/2022

  Celcuity Inc. announced that the U.S. Food and Drug Administration has granted gedatolisib Breakthrough Therapy designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor.

• Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

  5/26/2022

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences.

• Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates

  5/16/2022

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, announced financial results for the first quarter ended March 31, 2022 and other recent business progress.

• Celcuity Inc. Announces $100 Million Private Placement

  5/16/2022

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors in a private placement for the purchase of common stock.

• Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call

  5/9/2022

  Celcuity Inc. today announced that it will release its financial results for the first quarter 2022 after the stock market close on Monday, May 16, 2022.

• Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences

  4/5/2022

  Celcuity Inc. today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following virtual investor conferences: A company presentation at the 21st Annual Needham Healthcare Conference at 3:45 p.m. ET on Tuesday, April 12, 2022.

• Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates

  3/23/2022

  Celcuity Inc. announced financial results for the fourth quarter and full year ended December 31, 2021, the design for its pivotal Phase 3 trial for gedatolisib, an investigational pan-PI3K/mTOR inhibitor, and other recent business progress.

• Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call

  3/16/2022

  Celcuity Inc. today announced that it will release its financial results for the fourth quarter and full year 2021 after the stock market close on Wednesday, March 23, 2022.

• Celcuity to Participate in the Cowen 42nd Annual Health Care Conference

  3/2/2022

  Celcuity Inc. today announced its participation in the virtual Cowen 42nd Annual Health Care Conference to be held March 7-9, 2022.

• Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update

  1/18/2022

  Celcuity Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's lead drug candidate, gedatolisib, for the treatment of patients with HR+/HER2- metastatic breast cancer after progression on CDK4/6 therapy.

• Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium

  12/10/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, presented a poster at the 2021 San Antonio Breast Cancer Symposium with updated results from a four-arm Phase 1b expansion study.

• Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium

  12/2/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, announced that an abstract has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium, which is being held virtually and in-person from December 7-10, 2021.

• Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

  11/29/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, announced the addition of two senior executives to its corporate management team.